Intermittent subcutaneous injections are used as an 'on demand' strategy for disabling refractory ”off” periods, in patients already treated with an optimised oral anti-Parkinson therapy.1
Delays in turning “on” reflect a delay in the absorption of levodopa and a subsequent delay in crossing the blood–brain barrier. This may be a result of delayed gastric emptying (gastroparesis) or presence of intestinal protein that competes with L-dopa absorption.2
For patients where levodopa absorption and therefore symptom relief becomes unreliable, Dacepton® and the D-mine® Pen may help to provide a fast and reliable "on".
For more information on how to use the D-mine® Pen, skincare and FAQs please see our "D-mine® Pen Brochure"
The D-mine® has been designed to be easy to use and works in much the same way as an insulin pen. It is a reusable pen which houses a 3ml Dacepton® Cartridge.
To view a video introduction to the D-mine® Pen, please click here.
1. Manson AJ, Turner K, Lees A. (2002) Apormorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients. Movement Disorders
2. Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F. (2016) Apormorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease. Movement Disorders Clinical Practice